In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micromet Gets $14M Upfront From Amgen For BiTE Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

The world's largest biotech is investing in the research of BiTE antibodies against three undisclosed solid tumor targets.
Advertisement

Related Content

Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Micromet Reacquires Full North American Rights To Blinatumomab
Micromet Gets $12M Upfront From Sanofi For Discovery-Stage Oncology Antibody

Topics

Advertisement
UsernamePublicRestriction

Register

PS072494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel